miRNA regulation, antitumor activity, and molecular modeling by Naproxen-1,2,4-triazole compound in human Breast cancer

Abstract

In this study, a new 1,2,4-triazole ring that has a 2-fluorophenyl ring was synthesized using (S)-Naproxen as the starting molecule. The target compound was characterized using spectroscopic methods such as FT-IR, 1H-NMR, 13C-NMR, and HR-MS. In molecular modeling studies, compound (4a) was used to control for the Bcl-2 apoptotic marker. The main aim was to show that the MDA-MB-231 cell line developed growth inhibition in a dose-dependent manner after compound treatment. The results showed that compound (4a) inhibited the motility of MDA-MB-231 cells. Compound (4a) at 75, 150, and 300 µM concentrations significantly reduced the viability of MDA-MB-231 cells compared to the control group. IC50 value of the compound (4a) for 48 h was 57.6 µM. In our study, for the first time, miR-133a-5p was significantly up-regulated in MDA-MB-231 breast cancer cells treated with compound (4a) at different concentrations compared to the control group. As such, miR-133a-5p could play an essential role in tumorigenesis by targeting Bcl-2 in MDA-MB-231 and may be a biomarker for therapeutic targets in breast cancer treatment.

Keywords

• Naproxen
• Bcl-2
• MDA-MB-231
• Molecular Modeling
• miR-133a-5p

References

1. [1] Hassanpour SH, Dehghani M. Review of cancer from the perspective of molecular. J Can Res Practice. 2017; 4: 127-129. https://doi.org/10.1016/j.jcrpr.2017.07.001
2. [2] Upadhyay A, Cancer: An unknown territory; rethinking before going ahead. Genes & Diseases. 2021; 8: 655-661. https://doi.org/10.1016/j.gendis.2020.09.002
3. [3] Blackadar CB. Historical review of the causes of cancer. World J Clin Oncol. 2016; 10, 7(1): 54-86. http://dx.doi.org/10.5306/wjco.v7.i1.54
4. [4] Azamjah N, Soltan-Zadeh Y, Zayeri F. Global Trend of Breast Cancer Mortality Rate: A 25-Year Study. Asian Pac J Cancer Prev. 2019; 20 (7): 2015-2020. https://doi.org/10.31557/APJCP.2019.20.7.2015
5. [5] Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, Marotti J, Connolly JL, Schnitt SJ, Collins LC. Traditional Breast Cancer Risk Factors in Relation to Molecular Subtypes of Breast Cancer. Breast Cancer Res Treat. 2012; 31(1): 159–167. https://doi.org/10.1007/s10549-011-1702-0
6. [6] Barnard ME, Boeke CE, Tamimi, RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochimica et Biophysica Acta. 2015; 1856: 73–85. https://doi.org/10.1016/j.bbcan.2015.06.002
7. [7] Tong CWS, Wu M, Cho WCS, To KKW. Recent Advances in the Treatment of Breast Cancer. Front Oncol. 2018; 8:227: 1-10. https://doi.org/10.3389/fonc.2018.00227
8. [8] Chıu TL, Su CC. Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-κBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med. 2009; 23: 469-475. https://doi.org/10.3892/ijmm_00000153

9. [9] Beberok A, Wrześnıok D, Rok J, Rzepka Z, Respondek M, Buszman E. Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway. Int J Onc. 2018; 52: 1727-1737. https://doi.org/10.3892/ijo.2018.4310
10. [10] Singh R, Mo YY. Role of microRNAs in breast cancer. Can Bio Ther. 2013; 14:3: 201–212. https://doi.org/10.4161/cbt.23296
11. [11] Mulrane L, McGee SF, Gallagher WM, O'Connor DP. miRNA Dysregulation in Breast Cancer. Cancer Res. 2013; 73(22): 6554-6562. https://doi.org/10.1158/0008-5472.CAN-13-1841
12. [12] Han MI, Atalay P, Tunç CÜ, Ünal G, Dayan S, Aydın O, Küçükgüzel SG. Design and synthesis of novel (S)-Naproxen hydrazide-hydrazones as potent VEGFR-2 inhibitors and their evaluation in vitro/in vivo breast cancer models. Bioorg Med Chem. 2021; 37: 116097. https://doi.org/10.1016/j.bmc.2021.116097
13. [13] Han MI., Küçükgüzel ŞG, Anticancer and Antimicrobial Activities of Naproxen and Naproxen Derivatives. Mini-Rev Med Chem. 2020; 20: 1300-1310. https://doi.org/10.2174/1389557520666200505124922
14. [14] Han Mİ, Bekçi H, Uba AI, Yıldırım Y, Karasulu E, Cumaoğlu A, Karasulu HY, Yelekçi K, Yılmaz Ö, Küçükgüzel ŞG. Synthesis. Molecular modeling. in vivo study. and anticancer activity of 1.2.4‐triazole containing hydrazide–hydrazones derived from (S)‐naproxen. Arch Pharm Chem Life Sci. 2019; 352: 1-14. https://doi.org/10.1002/ardp.201800365
15. [15] Han Mİ, Bekçi H, Cumaoğlu A, Küçükgüzel ŞG. Synthesis and characterization of 1.2.4-triazole containing hydrazide-hydrazones derived from (S)-Naproxen as anticancer agents. Marmara Pharm J. 2018; 22(4): 559-569. https://www.jrespharm.com/abstract.php?id=642
16. [16] Han Mİ, Ince U, Gündüz MG, Küçükgüzel ŞG. Synthesis, Antimicrobial Evaluation, and Molecular Modeling Studies of New Thiosemicarbazide-Triazole Hybrid Derivatives of (S)-Naproxen. Chem Biodiversity. 2022; 19: e202100900. https://doi.org/10.1002/cbdv.202100900
17. [17] Han MI, Tunç CU, Atalay P, Erdogan Ö, Unal G, Bozkurt M, Aydın Ö, Çevik Ö, Kuçukguzel SG. Design, synthesis, and in vitro and in vivo anticancer activity studies of new (S)-Naproxen thiosemicarbazide/1,2,4-triazole derivatives. New J Chem. 2022; 46: 6046-6059. https://doi.org/10.1039/D1NJ05899A
18. [18] Tunc CU, Kursunluoglu G, Akdeniz M, Kutlu AÜ, Han Mİ, Yerer MB, Aydin Ö. Investigation of Gold Nanoparticle Naproxen-Derived Conjugations in Ovarian Cancer. ACS Mater Au. 2023; 3: 483−491. https://doi.org/10.1021/acsmaterialsau.3c00033
19. [19] Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015; 20(7): 13384-421. https://doi.org/10.3390/molecules200713384
20. [20] Pinzi L, Rastelli G. Molecular Docking: Shifting Paradigms in Drug Discovery. Int J Mol Sci. 2019; 20(18). https://doi.org/10.3390/ijms20184331
21. [21] Gunasekaran V, Dhakshinamurthy SS. Computational Insights into the Interaction of Pinostrobin with Bcl-2 Family Proteins: A Molecular Docking Analysis. Asian Pac J Cancer Prev. 2024; 25(2): 507-512. https://doi.org/10.31557/apjcp.2024.25.2.507
22. [22] Ismail HS, Khalil, A, Taha RA, et al., Design, molecular modelling and synthesis of novel benzothiazole derivatives as BCL-2 inhibitors. Sci Rep. 2023; 13(1): 15554. https://doi.org/10.1038/s41598-023-41783-1
23. [23] Liu Y, Grimm M, Dai WT, Hou MC, Xiao ZX, Cao Y. CB-Dock: a web server for cavity detection-guided protein–ligand blind docking. Acta Pharmacologica Sinica. 2020; 41(1): 138-144. https://doi.org/10.1038/s41401-019-0228-6
24. [24] Jia CY, Li JY, Hao GF, Yang GF. A drug-likeness toolbox facilitates ADMET study in drug discovery. Drug Discovery Today. 2020; 25(1): 248-258. https://doi.org/10.1016/j.drudis.2019.10.014
25. [25] Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7: 42717. https://doi.org/10.1038/srep42717
26. [26] Moroy G, Martiny VY, Vayer P, Villoutreix BO, Miteva MA. Toward in silico structure-based ADMET prediction in drug discovery. Drug Discovery Today. 2012; 17(1): 44-55. https://doi.org/10.1016/j.drudis.2011.10.023
27. [27] Martin YC. A Bioavailability Score. Journal of Medicinal Chemistry. 2005; 48(9): 3164-3170. https://doi.org/10.1021/jm0492002
28. [28] Daina A, Zoete V. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem. 2016; 11(11): 1117-1121. https://doi.org/10.1002/cmdc.201600182
29. [29] Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 2015; 58(9): 4066-72. https://doi.org/10.1021/acs.jmedchem.5b00104
30. [30] Tong Z, Cui Q, Wang J, Zhou Y. TransmiR v2.0: an updated transcription factormicroRNA regulation database, Nucleic Acids Res. 2019; 47: 253–258. https://doi.org/10.1093/nar/gky1023
31. [31] Hsieh TH, Hsu CY, Tsai CF, Long CY, Chai CY, Hou MF, Lee JN, Wu DC, Wang SC, Tsai EM. miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. Oncotarget. 2015; 6(1): 494-509. https://doi.org/10.18632/oncotarget.2674
32. [32] Hua YT, Xu WX, Li H, Xia M. Emerging roles of MiR-133a in human cancers. J Cancer. 2021; 12(1): 198-206. https://doi.org/10.7150/jca.48769
33. [33] Babaei K, Shams S, Keymoradzadeh A, Vahidi S, Hamami P, Khaksar R, Norollahi SE, Samadani AA. An insight into microRNAs performance in carcinogenesis and tumorigenesis; an overview of cancer therapy. Life Sci. 2020; 240: 117077. https://doi.org/10.1016/j.lfs.2019.117077
34. [34] Lamichhane S, Mo JS, Sharma G, Joung SM, Chae SC. MIR133A regulates cell proliferation, migration, and apoptosis by targeting SOX9 in human colorectal cancer cells. Am J Cancer Res. 2022; 12(7): 3223-3241. https://pmc.ncbi.nlm.nih.gov/articles/PMC9360235/
35. [35] Yan H, Huang W, Chen C, Zhang X, Zhu K, Yuan J. MiR-133a/CD47 axis is a novel prognostic biomarker to promote triple negative breast cancer progression. Pathol Res Pract. 2023; 244: 154400. https://doi.org/10.1016/j.prp.2023.154400
36. [36] Barartabar Z, Moini N, Abbasalipourkabir R, Mesbah-Namin SA, Ziamajidi N. Investigation of miR-133a, miR-637 and miR-944 genes expression and their relationship with PI3K/AKT signaling in women with breast cancer. Journal of Cancer Research and Clinical Oncology. 2023; 149, 9: 6115-6129. https://doi.org/10.1007/s00432-023-04583-8
37. [37] Touré BB, Miller-Moslin K, Yusuff N, Perez L, Doré M, Joud C, Michael W, DiPietro L, van der Plas S, McEwan M, Lenoir F, Hoe M, Karki R, Springer C, Sullivan J, Levine K, Fiorilla C, Xie X, Kulathila R, Herlihy K, Porter D, Visser M. The Role of the Acidity of N-Heteroaryl Sulfonamides as Inhibitors of Bcl-2 Family Protein–Protein Interactions. ACS Medicinal Chemistry Letters. 2013; 4(2): 186-190. https://pmc.ncbi.nlm.nih.gov/articles/PMC4027142/
38. [38] Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, Lepore R, Schwede T. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018; 46: 296-303. https://doi.org/10.1093/nar/gky427
39. [39] Tam B, S Sinha, Wang SM. Combining Ramachandran plot and molecular dynamics simulation for structural-based variant classification: Using TP53 variants as model. Comput Struct Biotechnol J. 2020; 18: 4033-4039. https://doi.org/10.1016/j.csbj.2020.11.041
40. [40] Sezer G, Sahin F, Onses MS, Cumaoğlu A. Activation of epidermal growth factor receptors in triple-negative breast cancer cells by morphine; analysis through Raman spectroscopy and machine learning. Talanta. 2024; 272: 125827. https://doi.org/10.1016/j.talanta.2024.125827
41. [41] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402–408. https://doi.org/10.1006/meth.2001.1262